

2024 Annual General Meeting – Notice of Reconvened Meeting

Melbourne, Australia; 27 November 2024: Starpharma (ASX: SPL, US OTC: SPHRY) announces that its Annual General Meeting (AGM) that was adjourned on Tuesday, 26 November 2024, will reconvene on Friday, 29 November 2024, at 3:00 pm (Melbourne time).

As noted during the AGM on 26 November 2024, the Chair exercised discretion to adjourn one item of business, being the vote on Resolution 1 - Adoption of the Remuneration Report. This is the result of an offshore custodian needing additional time to amend votes on behalf of beneficial owners.

Details of the adjourned Resolution 1 are included in the [Notice of Annual General Meeting 2024](https://starpharma.com/assets/asxannouncements/241024-notice-of-agm-with-proxy-paper.pdf) that was announced on 28 October 2024, available on the ASX Market Announcements Platform and Starpharma's website (<https://starpharma.com/assets/asxannouncements/241024-notice-of-agm-with-proxy-paper.pdf>).

Shareholders and proxy holders can participate in the reconvened meeting online as per the Notice of AGM instructions or in person at the RACV City Club, 501 Bourke Street, Melbourne, Victoria, 3000.

Resolutions 2, 3 and 4 were carried at the 26 November 2024 meeting, and the results of these resolutions were [announced](https://starpharma.com/assets/uploads/2024-11/241126-2024-annual-general-meeting-results-of-meeting.pdf) to the market (<https://starpharma.com/assets/uploads/2024-11/241126-2024-annual-general-meeting-results-of-meeting.pdf>).

Shareholders may vote on Resolution 1 at the reconvened AGM either in person or by using the online Computershare Meeting Platform, details of which are set out in the Notice of AGM. Proxy instructions for Resolution 1 submitted before the commencement of the AGM on 26 November still stand.

Shareholders wishing to submit new or amended proxy instructions for Resolution 1 are now able to do so before 3.00 pm on 27 November 2024 (48 hours prior to the recommencement of the meeting Melbourne time).

A recording of the reconvened AGM will be made available on Starpharma's website as soon as practicable after the meeting.

About Starpharma

Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](#).



WE Communications

Hannah Howlett
+61 450 648 064
WE-AUStarPharma@we-worldwide.com

Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.